GANX stock sentiment todayGain Therapeutics Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
GANX
Gain Therapeutics IncA binary-outcome biotech play with a promising Parkinson’s candidate (GT-02287) but high cash-burn risk and significant technical overhead.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GANX. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by clinical trial anticipation rather than revenue. Retail chatter focuses on the potential for GT-02287 to be a disease-modifying treatment for GBA1-Parkinson’s, but institutional interest is tempered by the recent lack of major news flow.
- ·Anticipation of Phase 1b clinical data for GT-02287
- ·Magellan platform AI drug discovery potential
- ·Low float volatility making it a target for day traders
Financial
Classic pre-revenue biotech profile; significant net losses and reliance on equity financing. The balance sheet provides a limited runway, requiring successful milestones to avoid dilutive capital raises.
- ·Negative EBITDA and Net Income
- ·High Cash Burn rate relative to market cap
- ·Price-to-Book ratio indicates market skepticism of platform value
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Clinical failure of the lead asset GT-02287
- ·Imminent need for dilutive secondary offerings
- ·Extreme sensitivity to interest rate environments affecting small-cap biotech
Peer temperature
How direct competitors stack up against GANX right now.
- COLDSNCEScience 37 Holdings
COLDER — faces similar liquidity issues but lacks the high-upside biological MOA that GANX possesses.
See full analysis → - HOTDNLDenali Therapeutics
HOTTER — significantly more de-risked with a deep pipeline and massive strategic partnerships with Biogen and Takeda.
See full analysis → - NEUTRALPRTAProthena Corporation
HOTTER — stronger institutional backing and more advanced stage neurodegenerative programs despite higher valuation.
See full analysis →
- GANX-33.1%
- SNCE—
- DNL-4.5%
- PRTA+0.2%
Analyst price target
Consensus average of 5 analysts · median 8.00
Source: StockAnalysis.com · updated 2026-10-05
AI-generated analysis for informational purposes only. Not financial advice.